A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 12 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Feb 2017.
- 13 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2017.